Puma Biotech (PBYI) Tops Q1 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel
May 10, 2018 5:09 PM EDTStifel lowered its price target on Puma Biotechnology (NASDAQ: PBYI) to $87.00 (from $95.00) while maintaining a Buy rating.
Analyst Alex Schwartz commented, "Yesterday Puma reported 1Q18 numbers that included $66.5 million in revenue and a $24.3 million net loss. Nerlynx revenues of $36.0 million were below our $42.1 million... More
Buy the Puma Biotechnology (PBYI) Dip - Citi
May 10, 2018 12:32 PM EDTCiti analyst Yigal Nochomovitz came out to defend Puma Biotechnology (NASDAQ: PBYI), saying the sell-off is overdone and to buy the dip.
He said the Possible explanations in order of likelihood 1) Lower apparent demand (NRx / new specialty pharmacy pt adds) in April (~230 / 280) vs. March (~300 / 342), 2)... More
